semaglutide mash fda approval The has approved Wegovy (semaglutide) as a treatment for metabolic-associated steatohepatitis (MASH) with moderate-to-advanced scarring, a serious liver condition affecting approximately 6% of US adults. Key highlights of drug development program WEGOVY GETS APPROVAL: The weight-loss

The new guidelines specifically state that GLP-1RA is effective in lowering blood glucose and partially restoring pancreatic beta-cell function, as well as in lowering body weight, improving lipid profile and protecting kidney function

Gallbladder Disorders Weight loss is a known risk factor for gallstones

Evidence for specific clinical outcomes from subcutaneous lipotropic injections is still evolving, and a licensed provider can help set realistic expectations

10.1016/S0896-6273(03)00568-3 Neuron 34 DawsonT

Studies on rodents have shown GLP-1 receptor agonists can have antidepressant effects, but only with long-term use

However, its important to know that this shouldnt be your only deciding factor when youre choosing between medications, and ultimately, the final decision on your treatment is down to the prescriber or consultant that you speak to